AM-6545 is a drug which acts as a peripherally selective silent antagonist for the CB1 receptor and was developed for the treatment of obesity. Other cannabinoid antagonists such as rimonabant have been marketed for this application but have subsequently been withdrawn from sale because of centrally mediated side effects such as depression and nausea.
This page contains content from the copyrighted Wikipedia article "AM-6545"; that content is used under the GNU Free Documentation License (GFDL). You may redistribute it, verbatim or modified, providing that you comply with the terms of the GFDL.
